Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 25, 2025Expert Opinion on Biological Therapy

Advanced therapies targeting IL-23: clinical outcomes in ulcerative colitis

View Full Paper
Ask AI
Bookmark
Share

Authors

SSSilvia SalvatoriIMIrene MarafiniAFAntonio Fonsi

Discussion

Loading...

Member takes

Overview

Review highlights IL-23 therapies improving clinical outcomes in ulcerative colitis, suggesting new treatment strategies for patients.

Key Points

  • IL-23 inhibitors have shown significant efficacy in maintaining remission in ulcerative colitis.
  • Current therapies aim to promote mucosal healing and symptom relief in patients with moderate-to-severe UC.
  • Ustekinumab and selective IL-23p19 inhibitors provide promising safety profiles and efficacy based on post-marketing studies.
  • Emerging oral therapies may improve patient adherence and accessibility to effective treatments for ulcerative colitis.

Cite This Study

Salvatori et al. (2025) studied this question.

synapsesocial.com/papers/689a0627e6551bb0af8ce234https://doi.org/10.1080/14712598.2025.2539423
View Full Paper
Ask AI
Bookmark
Share